Ginkgo Bioworks stock down 81% in 2024, facing financial struggles and uncertain path to profitability.

From NASDAQ.: 2024-07-14 08:05:00

Ginkgo Bioworks’ stock (NYSE: DNA) has taken a dive, with shares down by 81% in 2024. The company plans to cut costs by 25% and reduce its workforce, aiming for positive EBITDA in 2026. However, declining revenue raises concerns about profitability. Despite collaborations with big players in biopharma, Ginkgo needs major changes to avoid running out of cash. The investing thesis is weakening, so caution is advised for potential investors. Other stocks may offer better growth opportunities.

Ginkgo Bioworks’ financial struggles and uncertain path to profitability make it risky for new investors. The company faces challenges in improving margins, scaling capabilities, and generating revenue. With poor biosecurity services and a collapsing segment, caution is advised towards investing in Ginkgo Bioworks until it proves its ability to become profitable. The risk outweighs the potential rewards at this time.



Read more at NASDAQ.: Down 81% in 2024, Is Ginkgo Bioworks Stock Still a Buy?